Sumitomo Pharma America to Present Preliminary Clinical Data Evaluating Investigational Oncology Agents TP-3654 and DSP-5336 at the American Society of Hematology Annual Meeting

/PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) today announced preliminary clinical data for investigational agents TP-3654, a selective oral PIM1 kinase...

Related Keywords

San Diego Convention Center ,California ,United States ,San Diego ,Cambridge ,Cambridgeshire ,United Kingdom ,Canada ,Japan ,American ,Diego Marina ,Sumitomo Pharma America ,Huax Menin ,Sumitomo Pharma ,Jatin Shah ,Sumitomo Pharma America Inc ,Sumitomo Pharma Canada Inc ,American Society Of Hematology ,Linkedin ,Marriott Marquis ,Prnewswire Sumitomo Pharma America Inc ,Sumitomo Pharma Co Ltd ,Us Sumitomo Pharma America Inc ,Oncology Development ,Drug Administration ,Data Includes New Clinical Results ,Refractory Myelofibrosis ,Refractory Acute Leukemia ,Pharma America ,American Society ,Annual Meeting ,Chief Oncology Development Officer ,New Therapeutic Frontiers ,San Diego Marina ,Pacific Ballroom Salons ,Myeloid Leukemias ,Investigational Therapies ,Excluding Transplantation ,Orphan Drug Designation ,Sumitomo Pharma Canada ,Sumitomo Pharma Switzerland Gmbh ,Future Med ,Biotechnology ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,